Yongjie Xie
Overview
Explore the profile of Yongjie Xie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li Y, Li Z, Sun D, Ni B, Tan M, Shay A, et al.
bioRxiv
. 2025 Jan;
PMID: 39763887
Cystine/cysteine is critical for antioxidant response and sulfur metabolism in cancer cells and is one of the most depleted amino acids in the PDAC microenvironment. The effects of cystine limitation...
2.
Zhou T, Yan J, Xu B, Zhang Y, Mao G, Xie Y, et al.
Cancer Lett
. 2024 Dec;
611():217408.
PMID: 39710057
Senescent cells are in a stable state of cell cycle arrest, leading to a natural barrier to tumorigenesis. Senescent cells secrete a pool of molecules, including cytokines, chemokines, proteases, and...
3.
Ding J, Xie Y, Liu Z, Zhang Z, Ni B, Yan J, et al.
Gastroenterology
. 2024 Nov;
168(3):539-555.e5.
PMID: 39566663
Background & Aims: Gemcitabine combined with albumin-paclitaxel (AG) is a crucial therapeutic option for pancreatic ductal adenocarcinoma (PDAC). However, the response to chemotherapy is relatively poor, with rapid development of...
4.
Yan J, Xie Y, Liu Z, Yang Y, Zhou T
J Immunother Cancer
. 2024 Nov;
12(11).
PMID: 39542653
Background: Neoadjuvant therapy with trastuzumab, pertuzumab and paclitaxel (THP) has significantly improved the prognosis of patients with human epidermal growth factor receptor 2 (HER2) breast cancer (BC). However, there remains...
5.
Xie Y, Liu Z, Zhang J, Li G, Ni B, Shi C, et al.
iScience
. 2024 Nov;
27(11):111178.
PMID: 39524324
In this study, we delved into the intrinsic cellular components and transcriptomic signatures characterizing breast-invasive micropapillary carcinoma (IMPC). Employing bulk RNA sequencing, we conducted differential gene expression and functional profiles...
6.
Shang X, Xie Y, Yu J, Zhang C, Zhao G, Liang F, et al.
Cancer Cell
. 2024 Oct;
42(10):1747-1763.e7.
PMID: 39406186
In this phase II study, 47 patients with locally advanced, resectable esophageal squamous cell carcinoma (ESCC) received three cycles of pembrolizumab plus chemotherapy, followed by Da Vinci robot-assisted surgery. The...
7.
Wang B, Pan Y, Xie Y, Wang C, Yang Y, Sun H, et al.
Biol Proced Online
. 2024 Sep;
26(1):29.
PMID: 39342097
Pancreatic cancer is a devastating malignancy with a high mortality rate, poor prognosis, and limited treatment options. The tumor microenvironment (TME) plays a crucial role in tumor progression and therapy...
8.
Lyu J, Zhang X, Xiong S, Wu H, Han J, Xie Y, et al.
Front Pediatr
. 2024 Sep;
12:1440190.
PMID: 39239470
Introduction: Specialized care is essential for the recovery of children with cerebral palsy (CP). This study investigates how different care modes impact the gut microbiota. Methods: Fecal samples from 32...
9.
Zou Y, Xie Y, Huang J, Liang Y, Chang S, Wang H, et al.
Surgery
. 2024 Aug;
176(5):1466-1474.
PMID: 39191600
Background: This study aimed to evaluate the impact of adjuvant chemotherapy on survival in patients with stage I pancreatic ductal adenocarcinoma, stratified according to pathologic risk factors. Methods: A total...
10.
Zhou T, Hou X, Yan J, Li L, Xie Y, Bai W, et al.
Gut
. 2024 Aug;
73(12):1984-1998.
PMID: 39187291
Objective: The objective of this study is to improve the efficacy of CLDN18.2/CD3 bispecific T-cell engagers (BiTEs) as a promising immunotherapy against pancreatic ductal adenocarcinoma (PDAC). Design: Humanised hCD34/hCD3e, Trp53KrasPdx1-Cre...